SCHEMBL3012970

SCHEMBL3012970

Cc1cccc(C)c1-c1csc(N2CCC(S(=O)(=O)c3cc(C(F)(F)F)ccc3Cl)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.42
RAB9A P51151 5/20 0.41
NPC1 O15118 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003910 0.91 RAF1 (0.42) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3009901 0.90 RAF1 (0.43) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3013629 0.88 MEN1 (0.50) ARRAB9AMEN1KMT2AL3MBTL1
SCHEMBL3003914 0.88 SMN1; SMN2 (0.47) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3021903 0.88 AR (0.49) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3009295 0.87 AR (0.43) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3008837 0.87 SMN1; SMN2 (0.49) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3009425 0.86 MEN1 (0.49) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3006949 0.86 AR (0.50) ARRAB9ANPC1MEN1KMT2A
SCHEMBL3016070 0.85 CTSS (0.48) ARRAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.